{'fraction_non_alphanumeric': 0.0426098535286285, 'fraction_numerical': 0.03395472703062583, 'mean_word_length': 4.825581395348837, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Rheumatoid arthritis heralded by the hypereosinophilic syndrome

bleeding warfarin-treated patients with INR ≤ 5.0. Pretransfusion INR was ≤1.5 in 51/128 episodes (40%): 10 were given as part of the massive transfusion protocol and a further 22 involved clinically significant bleeding. Median pre-transfusion INR was 1.7 (interquartile range 1.4–2.3). The magnitude of ΔINR was proportional to baseline INR, as previously reported. Our regression equations for ΔINR per one unit are FFP = 0.28 (baseline INR) − 0.36; r = 0.60 (237 episodes) and ΔINR per 500 IU PCC = 0.20 (baseline INR] − 0.14; r = 0.50 (39 episodes). The regression coefficients were not significantly different, as expected from limited sample size. Many FFP transfusions did not conform to Patient Blood Management Guidelines and were not clinically required. Guidance recommends against the use of FFP in warfarin reversal with INR ≤ 5.0 and in non-bleeding patients with liver failure/sepsis. Postoperative prescription of clotting factor replacement rely on clinical judgement, upon which point-of-care global haemostasis assays may help refine. The benefit of giving FFP during bleeding episodes with an INR ≤ 1.5 outside the setting of massive transfusion is unknown, requiring further research. PCC alone is adequate when reversing warfarin effect; whether it can replace FFP in other indications needs investigation. We recommend reinforcing education and monitoring of FFP use in hospitals to prevent its inappropriate use.